Funxional, Boehringer Ingelheim deal

The companies said Boehringer will acquire exclusive, worldwide rights to Funxional's somatotaxin portfolio. The portfolio's most advanced product is FX125L, an oral small molecule somatostatin receptor 2 (SSTR2) agonist, which has completed a Phase II trial for inflammatory conditions. Details were not disclosed. The deal also includes backup somatotaxins, including oral FX141L and topical FX87L - both of which are in preclinical development. Boehringer plans to initially develop FX125L for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Somatotaxins are a class of anti-inflammatory small molecules targeting SSTR. ...